MBX Biosciences' Hypoparathyroidism Treatment a 'Key Catalyst,' Oppenheimer Says

MT Newswires Live

2025/07/16

MBX Biosciences' (MBX) hypoparathyroidism drug, canvuparatide, is a "key catalyst" for the company as its potentially favorable efficacy to current treatments could be a $2 billion global peak sales opportunity, said Oppenheimer said in a Wednesday note.

Oppenheimer said its enthusiasm for MBX Biosciences stems from the company's precision endocrine peptide platform and its potential to "redefine standards" in endocrine and metabolic disease treatment.

The firm initiated coverage on MBX Biosciences with an outperform rating and a $38 price target.

Price: 12.40, Change: -1.00, Percent Change: -7.46

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2551129520"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551129520\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551129520?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 22:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551129520","market":"sh","top_or_hot":-1,"title":"MBX Biosciences' Hypoparathyroidism Treatment a 'Key Catalyst,' Oppenheimer Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MBX\">MBX Biosciences</a>' (MBX) hypoparathyroidism drug, canvuparatide, is a \"key catalyst\" for the company as its potentially favorable efficacy to current treatments could be a $2 billion global peak sales opportunity, said <a href=\"https://laohu8.com/S/OPY\">Oppenheimer</a> said in a Wednesday note.</p><p>Oppenheimer said its enthusiasm for MBX Biosciences stems from the company's precision endocrine peptide platform and its potential to \"redefine standards\" in endocrine and metabolic disease treatment.</p><p>The firm initiated coverage on MBX Biosciences with an outperform rating and a $38 price target.</p><p>Price: 12.40, Change: -1.00, Percent Change: -7.46</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MBX Biosciences' Hypoparathyroidism Treatment a 'Key Catalyst,' Oppenheimer Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMBX Biosciences' Hypoparathyroidism Treatment a 'Key Catalyst,' Oppenheimer Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-07-16 22:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MBX\">MBX Biosciences</a>' (MBX) hypoparathyroidism drug, canvuparatide, is a \"key catalyst\" for the company as its potentially favorable efficacy to current treatments could be a $2 billion global peak sales opportunity, said <a href=\"https://laohu8.com/S/OPY\">Oppenheimer</a> said in a Wednesday note.</p><p>Oppenheimer said its enthusiasm for MBX Biosciences stems from the company's precision endocrine peptide platform and its potential to \"redefine standards\" in endocrine and metabolic disease treatment.</p><p>The firm initiated coverage on MBX Biosciences with an outperform rating and a $38 price target.</p><p>Price: 12.40, Change: -1.00, Percent Change: -7.46</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2551129520","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551129520","pubTimestamp":1752677015,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"MBX Biosciences'  hypoparathyroidism drug, canvuparatide, is a \"key catalyst\" for the company as its potentially favorable efficacy to current treatments could be a $2 billion global peak sales opportunity, said Oppenheimer said in a Wednesday note.Oppenheimer said its enthusiasm for MBX Biosciences stems from the company's precision endocrine peptide platform and its potential to \"redefine standards\" in endocrine and metabolic disease treatment.The firm initiated coverage on MBX Biosciences with an outperform rating and a $38 price target.Price: 12.40, Change: -1.00, Percent Change: -7.46","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK7040":"食品零售","OPY":"奥本海默控股","MBX":"MBX Biosciences","BK4127":"投资银行业与经纪业"},"translate_title":"奥本海默表示，MBX Biosciences的甲状旁腺功能减退治疗是“关键催化剂”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MBX":1,"OPY":1,"MBX.AU":1},"content_text":"MBX Biosciences' (MBX) hypoparathyroidism drug, canvuparatide, is a \"key catalyst\" for the company as its potentially favorable efficacy to current treatments could be a $2 billion global peak sales opportunity, said Oppenheimer said in a Wednesday note.Oppenheimer said its enthusiasm for MBX Biosciences stems from the company's precision endocrine peptide platform and its potential to \"redefine standards\" in endocrine and metabolic disease treatment.The firm initiated coverage on MBX Biosciences with an outperform rating and a $38 price target.Price: 12.40, Change: -1.00, Percent Change: -7.46","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}